William E Fantegrossi Selected Research

William E Fantegrossi Research Topics

Disease

5	Psychotic Disorders (Schizoaffective Disorder) 01/2024 - 01/2011
5	Substance-Related Disorders (Drug Abuse) 09/2020 - 10/2011
4	Seizures (Absence Seizure) 10/2022 - 01/2011
4	Hypothermia 01/2022 - 09/2013
4	Hyperthermia 01/2018 - 05/2004
3	Marijuana Use 02/2018 - 01/2011
2	Opioid-Related Disorders (Opiate Addiction) 01/2019 - 02/2014
2	Catalepsy 01/2016 - 04/2012
1	Tremor (Tremors) 01/2022
1	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2020
1	Chronic Disease (Chronic Diseases) 01/2019
1	Schizophrenia (Dementia Praecox) 02/2018
1	Chest Pain (Chest Pains) 01/2018
1	Pheochromocytoma 08/2017
1	Tachycardia (Tachyarrhythmias) 11/2014
1	Visceral Pain 11/2014
1	HIV Infections (HIV Infection) 09/2014
1	Pain (Aches) 09/2013
1	Alcoholism (Alcohol Abuse) 06/2013
1	Cocaine-Related Disorders (Cocaine Addiction) 10/2011
1	Mental Disorders (Mental Disorder) 10/2011
1	Panic Disorder (Panic Attack) 01/2011
1	Hallucinations (Hallucination) 01/2011
1	Hypertension (High Blood Pressure) 01/2011
1	Respiratory Insufficiency (Respiratory Failure) 08/2009
1	Hyperalgesia 08/2009
1	Ataxia (Dyssynergia) 12/2005

Drug/Important Bio-Agent (IBA)

11	CannabinoidsIBA 01/2022 - 01/2011
3	Cocaine (Cocaine HCl)IBA 01/2024 - 10/2011
3	1-pentyl-3-(1-naphthoyl)indoleIBA 10/2022 - 09/2013
3	N-Methyl-3,4-methylenedioxyamphetamine (MDMA)IBA 01/2020 - 05/2004
3	Opioid Analgesics (Opioids)IBA 01/2019 - 02/2014
3	Serotonin (5 Hydroxytryptamine)IBA 02/2018 - 08/2017
3	SaltsIBA 01/2018 - 09/2014
2	Phencyclidine (Angel Dust)IBA 01/2024 - 01/2016
2	Morphine (MS Contin)FDA LinkGeneric 01/2024 - 11/2014
2	N- (1- amino- 3- methyl- 1- oxobutan- 2- yl)- 1- (5- fluoropentyl)- 1H- indazole- 3- carboxamideIBA 10/2022 - 01/2022
2	N- (1- amino- 3- methyl- 1- oxobutan- 2- yl)- 1- pentyl- 1H- indazole- 3- carboxamideIBA 10/2022 - 01/2018
2	5-F-ADB-PINACAIBA 10/2022 - 01/2022
2	Synthetic CathinoneIBA 09/2020 - 01/2018
2	LigandsIBA 01/2020 - 06/2013
2	Designer DrugsIBA 01/2020 - 01/2016
2	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2020 - 06/2013
2	EndocannabinoidsIBA 02/2018 - 06/2013
2	Dopamine (Intropin)FDA LinkGeneric 02/2018 - 01/2018
1	Cannabinoid Receptor AgonistsIBA 10/2022
1	ConvulsantsIBA 10/2022
1	Dronabinol (THC)FDA LinkGeneric 01/2022
1	RimonabantIBA 01/2022
1	VaccinesIBA 09/2020
1	Conjugate VaccinesIBA 09/2020
1	Buprenorphine (Subutex)FDA LinkGeneric 01/2019
1	norbuprenorphineIBA 01/2019
1	beta-Arrestin 1IBA 01/2019
1	Naltrexone (ReVia)FDA LinkGeneric 01/2019
1	Neurotransmitter Agents (Neurotransmitter)IBA 02/2018
1	Glutamic Acid (Glutamate)FDA Link 02/2018
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2018
1	Glutathione (Reduced Glutathione)IBA 08/2017
1	Clozapine (Clozaril)FDA LinkGeneric 01/2016
1	nuciferineIBA 01/2016
1	Amphetamine (Amfetamine)FDA LinkGeneric 01/2016
1	Antipsychotic Agents (Antipsychotics)IBA 01/2016
1	Serotonin 5-HT2 Receptor AgonistsIBA 01/2016
1	cathinoneIBA 09/2014
1	Methamphetamine (Desoxyn)FDA LinkGeneric 09/2014
1	N- (1- phenethylpiperidin- 4- yl)- N- phenylacetamideIBA 02/2014
1	JWH-073IBA 09/2013
1	sigma Receptors (sigma Receptor)IBA 10/2011
1	Proteins (Proteins, Gene)FDA Link 10/2011
1	Capsaicin (Zostrix)FDA Link 08/2009
1	Alfentanil (Alfenta)FDA LinkGeneric 08/2009
1	Ro 64-6198IBA 08/2009
1	salvinorin AIBA 12/2005
1	volinanserinIBA 05/2004
1	nantenineIBA 05/2004
1	Prazosin (Minipress)FDA LinkGeneric 05/2004

Therapy/Procedure

4	Therapeutics 09/2020 - 06/2013
3	Analgesia 01/2022 - 04/2012
1	Drug Therapy (Chemotherapy) 11/2018
1	Induced Hyperthermia (Thermotherapy) 05/2004